Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

77.70USD
16 Feb 2018
Change (% chg)

$-1.09 (-1.38%)
Prev Close
$78.79
Open
$78.21
Day's High
$79.13
Day's Low
$76.88
Volume
295,360
Avg. Vol
524,031
52-wk High
$82.96
52-wk Low
$45.11

Chart for

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $3,788.21
Shares Outstanding(Mil.): 48.75
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Agios Reports Qtrly Loss Per Share $1.81

* AGIOS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 14 2018

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

Jan 22 2018

UPDATE 3-Celgene to buy Juno for $9 bln to boost cancer pipeline

* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)

Jan 22 2018

Agios sizes up funding needs

Jan 19 (IFR) - Agios Pharmaceuticals pivoted from industry conferences to the capital markets, securing US$425m in a follow-on stock sale that meets its funding needs for the year.

Jan 19 2018

BRIEF-Agios prices offering of 7.09 mln shares at $67 per share

* AGIOS ANNOUNCES PRICING OF $475 MILLION PUBLIC OFFERING OF COMMON STOCK

Jan 18 2018

BRIEF-Agios Announces Proposed Offering Of Common Stock

* SAYS IT IS OFFERING TO SELL UP TO $400 MILLION OF ITS COMMON STOCK IN A PUBLIC OFFERING

Jan 17 2018

BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value

* AGIOS OUTLINES KEY 2018 PRIORITIES EXPANDING CLINICAL AND RESEARCH PROGRAMS TO DRIVE LONG TERM VALUE

Jan 08 2018

BRIEF-Agios Submits New Drug Application To The FDA For Ivosidenib

* AGIOS SUBMITS NEW DRUG APPLICATION TO THE FDA FOR IVOSIDENIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML AND AN IDH1 MUTATION

Dec 26 2017

BRIEF-Agios Pharmaceuticals Presents New Safety Data From Study on Leukemia Drug

* PRESENTS NEW SAFETY DATA FROM PHASE 1 EXPANSION STUDY EVALUATING ORAL IVOSIDENIB IN PATIENTS WITH R/R AML AND IDH1 MUTATION

Dec 11 2017

Promising responses seen with Agios leukemia drug in study

Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Dec 11 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.26 +0.55
Novartis AG (NOVN.S) CHF79.68 -1.12
Roche Holding Ltd. (ROG.S) CHF223.15 -2.35
Roche Holding Ltd. (RO.S) CHF226.00 -4.20
Sanofi SA (SASY.PA) €64.30 -0.20
AstraZeneca plc (AZN.L) 4,712.50 -27.00
GlaxoSmithKline plc (GSK.L) 1,308.60 -10.00
Eli Lilly and Co (LLY.N) $78.97 +0.95
Shire PLC (SHP.L) 3,110.50 -91.50
Shire PLC (3159084.L) -- --

Earnings vs. Estimates